Procainamide
From Wikipedia, the free encyclopedia
 |
|
|
Procainamide
|
|
| Systematic (IUPAC) name | |
| 4-amino-N-(2-diethylaminoethyl) benzamide | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C13H21N3O |
| Mol. mass | 235.325 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 85% (oral) |
| Protein binding | 15 to 20% |
| Metabolism | Hepatic (CYP2D6-mediated) |
| Half life | ~2.5 to 4.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | IV, IM, oral |
'Procainamide' (proe-KANE-a-mide) (INN, trade names Pronestyl, Procan, Procanbid) is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias, classified by the Vaughan Williams classification system as class Ia. Procanbid will no longer be manufactured.1
It blocks open sodium (Na+) channels and prolongs the cardiac action potential (outward potassium (K+) currents may be blocked). This results in slowed conduction, and ultimately the decreased rate of rise of the action potential, which may result in widening of QRS on electrocardiogram (ECG). This drug is used for both supraventricular and ventricular arrhythmias. For example, it can be used to convert new-onset atrial fibrillation, though it is suboptimal for this purpose.
Procainamide is administered intravenously or orally. When administered intravenously, a loading dose should first be given, though care should be taken not to cause hypotension. Procainamide's active metabolite is N-acetyl procainamide, which is stronger than procainamide and excreted by the kidneys and the renal system.
Adverse effects include rash, myalgia, hypersensitivity reactions (fever, agranulocytosis), Drug-Induced Lupus Erythematosus (particularly in slow-acetylators), and proarrhythmic effects (e.g., torsades de pointes). Treatment with procainamide can cause antibody production against cellular components, accounting for the systemic lupus erythematosus-like adverse reactions.
[edit] References
1. http://www.fda.gov/cder/drug/shortages/procanletter.pdf
|
|||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
